Lupin Limited Annual Report 2024 2024. S&p global csa score 2023: The local anesthesia drugs market size has grown strongly in recent years.
Lupin’s revenue came in at rs 5,197.4 crore. Revenue increased by 12% to rs 4,961 crore.
Lupin Reported A 52% Yoy Growth In Net Profit To Rs 368 Crore For March 2024 Quarter.
G lobal pharma major lupin limited has announced its debut in the s&p global sustainability yearbook 2024, underscoring its dedication to corporate.
The Analysts Expect The Pharma Company's Quarterly Revenue To Grow 16.4 Per Cent To Rs 5,156 Crore.
It will grow from $1.48 billion in 2023 to $1.62 billion in 2024 at a compound annual growth.
Contributed Around 70% To Lupin's Total Revenue.
Images References :
February 07, 2024 / 09:30 Pm Ist.
Q4 results 6 may 2024 updates:
Lupinโs Consolidated Revenues For The Financial Year 2023 Stood At โน16,641 Crore Compared To โน16,405 Crore In Fy22, With A Net Profit Of โน430 Crore In Fy23.
Lupin limited to report q2, 2024 results on nov 08, 2023 oct 26 lupin limited receives tentative approval from u.s.